H-CLAVEEVSL^-OH

Ref. 3D-PP48447

Produktinformation

• Name: H-CLAVEEVSL^-OH

Beschreibung

Peptide H-CLAVEEVSL^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-CLAVEEVSL^-OH include the following: Prediction and identification of new HLA-A-* 0201-restricted CD8-+ CTL epitopes from Aspergillusfumigatus antigen Asp f16 Z Zuo-tao, SUN Zheng, WAN Zhe - Chinese Journal of , 2011 - cjmycology.smmu.edu.cnhttp://cjmycology.smmu.edu.cn:81/Jweb_zgzj/EN/abstract/abstract8472.shtml Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection Z Sun, P Zhu, L Li, Z Wan, Z Zhao, R Li - European journal of clinical , 2012 - Springerhttps://link.springer.com/article/10.1007/s10096-012-1670-2 Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia W Zhou, J Yu, Y Li, K Wang - Experimental Hematology & Oncology, 2022 - Springerhttps://link.springer.com/article/10.1186/s40164-022-00353-3 cell-targeting alphaCD40 antibody construct coupled with viral or leukemia-specific antigens enhances dendritic cell maturation and activates peptide-responsive T cells S Schmitt, S Tahk, A Lohner, G Hanel - Frontiers in , 2020 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2020.602802/full Lohner S Schmitt, S Tahk - Hanel, G., Maiser,., Hauke, M , 2020 - scholarlypublications https://scholarlypublications.universiteitleiden.nl/access/item%3A3494351/download P04. 04 Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML S Schmitt, A Lohner, K Deiser, A Maiser, M Rothe - 2020 - jitc.bmj.comhttps://jitc.bmj.com/content/8/Suppl_2/A38.1.abstract Genetic alterations and checkpoint expression: mechanisms and models for drug discovery S Ding, S Li, S Zhang, Y Li - Regulation of Cancer Immune Checkpoints , 2020 - Springerhttps://link.springer.com/chapter/10.1007/978-981-15-3266-5_10 P04. 03 Immune modulatory vaccine directed against IDO1-expressing immune cells elicits T cell-mediated anti-tumor immunity and enhances anti-PD1 responses S Dey , E Sutanto-Ward, KL Kopp, JB DuHadaway - 2020 - jitc.bmj.comhttps://jitc.bmj.com/content/8/Suppl_2/A37.2.abstract Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin R Narayan, N Olsson , LE Wagar , BC Medeiros - PLoS , 2019 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0219547 HLA class I genotype Is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated acute myeloid leukemia R Narayan, A Niroula , T Wang, M Kuxhausen - and cellular therapy, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2666636723012046 Cellular therapy against public neoantigens PM Armistead - The Journal of clinical investigation, 2019 - Am Soc Clin Investighttps://www.jci.org/articles/view/126116 NPM 1 Mutations in AML-The Landscape in 2023 N Sharma, JL Liesveld - Cancers, 2023 - mdpi.comhttps://www.mdpi.com/2072-6694/15/4/1177 Neoantigens in hematologic malignancies MA Biernacki, M Bleakley - Frontiers in immunology, 2020 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00121/full La leucemie aiguaca« myeloblastique avec mutation de NPM1. M Bousquet - Hematologie, 2023 - search.ebscohost.comhttps://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=12647527&AN=162674587&h=ykN3zPOjBH1wdt2Lk19u1J%2BD6PhVWhDeLNjgEfR7myVxodLvg9yrwLnIQ9%2F%2BrkW%2Ba3fEI7iAmCPbUE3Agf1zrQ%3D%3D&crl=c The interplay between the genetic and immune landscapes of AML: mechanisms and implications for risk stratification and therapy LM Mendez , RR Posey, PP Pandolfi - Frontiers in Oncology, 2019 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fonc.2019.01162/full Nucleophosmin 1 mutations in acute myeloid leukemia J Zarka , NJ Short , R Kanagal-Shamanna, GC Issa - Genes, 2020 - mdpi.comhttps://www.mdpi.com/2073-4425/11/6/649 Human leukocyte antigens and adult acute myeloid leukemia: A first report from Lebanon H El Achkar, H Tamim , AK El Karaaoui, P Fermanian - Human Gene, 2023 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2773044123000189 Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia G Koutsoumpli, DI van der Lee, NC Groenland - Blood, 2022 - ashpublications.orghttps://ashpublications.org/blood/article/140/Supplement%201/10243/489588 Harnessing T cells for immunotherapy in AML: from molecule to therapy G Hanel - 2023 - edoc.ub.uni-muenchen.dehttps://edoc.ub.uni-muenchen.de/31848/1/Haenel_Gerulf.pdf Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia F Forghieri, G Riva, I Lagreca, P Barozzi - International Journal of , 2021 - mdpi.comhttps://www.mdpi.com/1422-0067/22/17/9159 Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia F Forghieri, G Riva, I Lagreca, P Barozzi, D Vallerini - Oncotarget, 2019 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368236/ http://cjmycology.smmu.edu.cn:81/Jweb_zgzj/CN/abstract/abstract8472.shtml P04. 05 Modulating tumor microenvironment with arginase-1 specific T cells E Martinenaite, MA Joergensen, REJ Mortensen - 2020 - jitc.bmj.comhttps://jitc.bmj.com/content/8/Suppl_2/A38.2.abstract Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia DI van der Lee, RM Reijmers - The Journal of , 2019 - Am Soc Clin Investighttps://www.jci.org/articles/view/97482 Mutated NPM1 as target for immunotherapy of acute myeloid leukemia DI Van Der Lee, HM Bijen, RS Hagedoorn - Blood, 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119806857 An HLA-A* 11: 01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML DI van der Lee, G Koutsoumpli, RM Reijmers - Cancers, 2021 - mdpi.comhttps://www.mdpi.com/2072-6694/13/21/5390 Abstract A044: Mutated NPM1 as target for immunotherapy of acute myeloid leukemia DI Lee, RM Reijmers , MW Honders - Cancer Immunology , 2019 - AACRhttps://aacrjournals.org/cancerimmunolres/article/7/2_Supplement/A044/469187 Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules A Liso , D Colau, R Benmaamar, A De Groot , W Martin - Leukemia, 2008 - nature.comhttps://www.nature.com/articles/2404887

• Marke: Biosynth